February 6, 2018 / 7:39 AM / 13 days ago

BRIEF-Redx Pharma Says First Patient Dosed In Phase 1/2a Trial Of RXC004

Feb 6 (Reuters) - Redx Pharma Plc:

* ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2A CLINICAL TRIAL OF ITS ORAL PORCUPINE INHIBITOR RXC004 IN PATIENTS WITH HARD TO TREAT CANCERS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below